Immune-related genes, such as CD8A, CD8B, GZMA, GZMB, and PRF1, that may indicate the function of tumor-infiltrating CD8 + T cells were considerably enriched in the group receiving combination therapy (Fig. 1E). This evidence concerns the gene CD8A and neoplasm.